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DNA methylation and the machinery involved in epigenetic regulation are key elements in the maintenance of cellular homeostasis.
Epigenetic mechanisms are involved in embryonic development and the establishment of tissue-specific expression, X-chromosome
inactivation and imprinting patterns, and maintenance of chromosome stability. The balance between all the enzymes and factors
involved in DNA methylation and its interpretation by different groups of nuclear factors is crucial for normal cell behaviour. In cancer
and other diseases, misregulation of epigenetic marks is a common feature, also including DNA methylation and histone post-
translational modifications. In this scenario, it is worth mentioning a family of proteins characterized by the presence of a methyl-CpG-
binding domain (MBDs) that are involved in interpreting the information encoded by DNA methylation and the recruitment of the
enzymes responsible for establishing a silenced state of the chromatin. The generation of novel aberrantly hypermethylated regions
during cancer development and progression makes MBD proteins interesting targets for their biological and clinical implications.
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DNA METHYLATION AND ITS MEDIATORS
DNA methylation is one of the most important mechanisms for
epigenetic silencing in mammals. It is a key element in
heterochromatin formation and maintenance, and is involved in
processes such as X-chromosome inactivation and gene imprint-
ing. DNA methylation also occurs at repetitive sequences to ensure
chromosome stability. DNA methylation is developed by a family
of DNA methyltransferase enzymes (DNMTs) that add a methyl
group to the fifth carbon position of cytosine when followed by
a guanine nucleotide. Methylation of DNA is accompanied by
histone post-translational modifications that modulate DNA
function, regulating chromatin structure and determining the
transcriptional state of the DNA wrapped around it.
The crosstalk between DNA methylation and histone modifica-
tions is established by different nuclear factors. Among them, it is
particularly remarkable a family of proteins that contain a Methyl-
CpG-binding domain commonly known as MBD proteins that
recognises single methylated CpG dinucleotide (Hendrich and
Bird, 1998). MBD family members recruit histone modifying and
chromatin remodeling complexes to methylated sites. The MBD
family of proteins is composed by five members namely MeCP2,
MBD1, MBD2, MBD3 and MBD4. MeCP2 was the first char-
acterised member and its 70 amino acids region corresponding to
the MBD was used for database identification of the remaining
MBD containing proteins. The binding affinity of MBD proteins
differs between them, as was demonstrated that MBD2 is the MBD
protein with higher methylated DNA-binding affinity in vitro
(Fraga et al, 2003).
DNA METHYLATION AND CANCER
In cancer, DNA methylation patterns are profoundly altered.
While there is a global decrease of CpG methylation,
promoter CpG island of tumour suppressor genes become
hypermethylated. In this landscape, chromosome instability
has been proposed to be associated with global genomic
demethylation, whereas aberrant hypermethylation of promoter
CpG island leads to gene inactivation. CpG islands are present
at the promoter region of approximately 60% of human
genes. These regulatory regions are commonly unmethylated
under physiological conditions, however in cancer the promoter
CpG island of many tumour suppressor genes become hyper-
methylated. Cellular pathways affected by CpG island hypermethy-
lation include cell cycle, apoptosis, cell adherence, DNA repair,
carcinogen metabolism and so on. For instance, genes such as
p16
INK4a, hMLH1 and BRCA1 are silenced in many types of cancer
due to CpG island hypermethylation. The mechanisms that define
which of these sequences become methylated is starting to be
evident and it has been suggested that it is a combination of
cellular selection of randomly methylated genes with targeted
pathways.
CpG island hypermethylation of tumour suppressor genes is
such a common fact in cancer that tumours can be classified
according to their methylation profile (Esteller et al, 2001; Esteller
2008). For instance, BRCA1 CpG island hypermethylation occurs
mainly in breast and ovarian cancer, and hMLH1 undergoes
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www.bjcancer.compromoter hypermethylation specifically in colon, gastric and
endometrial tumours profile (Esteller et al, 2001; Esteller 2008).
The characteristic methylation profiles associated with each
tumour type could be explained by selective advantage, the
methylation profile of a cell in a particular tissue confers a selective
advantage to the survival only in that environment.
It has also been reported that aberrant promoter hypermethyla-
tion patterns are also involved in miRNA silencing (Saito et al,
2006; Lujambio et al, 2007). miRNA are small non-coding RNAs
that inhibit protein expression of target genes. In cancer, miRNA
expression profiles differ between normal tissues and tumour
samples and between different tumour types (Lu et al, 2005), and
CpG island hypermethylation accounts for the transcriptional
silencing of a subset of miRNAs (Saito et al, 2006; Lujambio et al,
2007).
In cancer, not only DNA methylation but also histone
modifications are altered. Decreased levels of histone H4 lysine
16 monoacetylation and histone H4 lysine 20 trimethylation have
been described as common hallmark in cancer (Fraga et al, 2005).
Mutations in the machinery that are involved in epigenetic marks
are also involved in tumorigenesis, as reported for HDAC2
(Ropero et al, 2006).
In this context, it was suggested that MBD proteins were bound
to aberrantly methylated sequences, which trigger transcriptional
misregulation (Figure 1 and Table 1). In cancer cells MBD protein
levels are abnormal but this can be due to the increased cell
proliferation in these cells. In B-cell chronic lymphocytic
leukaemia, MeCP2 and MBD2 levels positively correlate with
Histone Methyl Transferases levels (Kn et al, 2004) suggesting that
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Figure 1 Mechanisms of epigenetic silencing by MBD proteins. Red and white circles represent methylated and unmethylated CpGs, respectively.
Table 1 MBD proteins bound to promoter hypermethylated CpG
islands of tumour suppressor genes
Target genes
MeCP2 RASSF1A, RARB2, GSTP1, MGMT, CDH1, CDH13, LTBP3, PARVG,
COLL11A2
MBD1 GSTP1, SOCS-1, COL11A2, PTPRN, FGF19, RARB2, CDH1
MBD2 BRCA1, MGMT, p16
INK4a, p14ARF, LTBP3, PTPRN, ER1, TIMP3,
CDH1, GSTP1, PRLR, PTPN4
MBD3 P21*, CHFR, PTPN4
MBD4 p16
INK4a, MHL1
p21* unmethylated CpG island. References for the target genes are included in the
text.
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over expressed and appears to be associated with oestrogen
receptor positivity (Muller et al, 2003). Polymorphisms in the
sequence of MBD proteins have been reported and some of them
seem to be associated with cancer risk, for instance, polymor-
phisms in MBD1 increase the overall risk of lung cancer (Jang et al,
2005) while polymorphisms in MBD2 is associated with reduced
risk of breast cancer among premenopausal women (Zhu et al,
2005). However, mutations in the MBD of MeCP2, MBD2 and
MBD3 have not been described in colon nor in endometrial cancer
cell lines (Ropero et al, 2006).
MBD protein occupancy of hypermethylated promoters in
tumour suppressor genes were reported in a large panel of human
cancer cell lines and their binding correlates with gene silencing
(Table 1). For instance, different MBD proteins were found
occupying the hypermethylated promoter of p16
INK4a or DAPK1
and the type of MBD bound to each promoter seems to be tumour
type and gene specific (Lopez-Serra et al, 2006). MBD proteins
have also been found to be associated with the hypermethylated
version of CpG islands embedded in miRNAs in colon cancer cells
(Lujambio et al, 2007).
More recently, interference of MBD proteins, using hairpin RNA
molecules (RNAi), were shown to release the transcriptional
expression of sets of hypermethylated genes without altering their
DNA methylation status (Lo ´pez-Serra et al, 2008). These results
support the notion that MBD proteins are involved in establishing
a crosstalk between DNA methylation and gene silencing
machinery recruitment but not in the establishment of DNA
methylation patterns (Lo ´pez-Serra et al, 2007). Some of the genes
silenced by DNA hypermethylation and the subsequent binding of
MBD proteins and chromatin reorganisation became expressed
again when we carried out MBD depletion. The re-expression of
these genes correlates with cell proliferation and tumorigenic
properties decrease. Taking into account the fact that MBD
proteins bind aberrantly hypermethylated promoters, they can also
be used to track novel genes that become epigenetically silenced in
cancer by combining chromatin immunoprecipitation assays with
hybridization on genomic microarrays (Ballestar et al, 2003).
MeCP2
MeCP2 is the founding member of the MBD family of proteins. It is
a 50kDa protein encoded by a gene located on the X-chromosome
which is composed of four exons that lead to two different splicing
variants called MeCP2a and MeCP2b depending on the presence or
absence of the exon 2.
This protein contains the MBD in the N-terminal region and a
transcriptional repression domain (TRD) near the C-terminal
region. The TRD domain includes a nuclear localization signal.
Repression by MeCP2 is mediated by chromatin remodelling
complexes recruitment to methylated DNA sequences (Figure 1).
The TRD domain interacts with Sin3A, a complex containing
histone desacetylase enzymes HDAC1 and HDAC2. Histone
deacetylation is not the only way in which MeCP2 represses
transcription and establishes heterochromatin formation, it is also
known that MeCP2 interacts with a complex containing lysine 9 of
histone H3 methyltransferase activity (Fuks et al, 2003) although
its identity is not yet known.
Mutations of the MBD and TRD domains of MeCP2 lead to Rett
syndrome, a neurodegenerative disease that affects mostly females.
Rett syndrome is characterised by mental retardation, autism,
microcephaly, breathing defects, characteristic hand movements
and others symptoms that appear between 6–18 months of age
after a normal initial development. MeCP2 knock out mice are
viable but show Rett syndrome symptoms like motor coordination
problems (Guy et al, 2001). It seems that MeCP2 plays an
important role in neural differentiation regulation since its lack
leads to this neurodegenerative disease. In cancer cells, inhibition
of MECP2 expression stops the growth of cancer prostate cells,
while its ectopic expression confers a growth advantage (Bernard
et al, 2006).
MBD1
MBD1 is a 55kDa protein encoded by a gene located on
chromosome 18. MBD1 contains the MBD in the N-terminal
region, a TRD in the C-terminal region and 2 or 3 CxxCxxC
domains located between the MBD and the TRD called CxxC1,
CxxC2 and CxxC3. The number of CxxCxxC domains depends on
alternative splicing events. Isoforms containing the CxxC3 are able
to bind unmethylated DNA so these proteins repress transcription
not only of methylated sequences but also of unmethylated regions
(Fujita et al, 2000).
MBD1 repressive activity were reported to be mediated by lysine
9 (K9) of histone H3 methylation through SETDB1 histone methyl-
transferase (HMT) recruitment (Klose and Bird, 2006) (Figure 1).
MBD1 also interacts with Suv39h, another HMT that methylates K9
of histone H3 (Fujita et al, 2003).
Mice lacking MBD1 have no development problems and exhibit
an apparently normal phenotype. However, pluripotency neuronal
cells show decreased neuronal differentiation and chromosome
instability (Klose and Bird, 2006).
MBD2
Methyl-CpG-binding domain 2 is a protein encoded on chromo-
some 18. It has two splicing variants, MBD2a (43, 5kDa) and
MBD2b (29.1kDa), that differ in the position of the translation
start site.
Repressive activity of MBD2 is mediated by MeCP1, an ATP
dependent chromatin remodelling complex formed by MBD2 and
Mi-2/NuRD complex (Fatemi and Wade, 2006) (Figure 1). Methyl-
CpG-binding domain 2 is also involved in methylation-dependent
gene silencing of Xist, a gene that plays an essential role in
X-chromosome inactivation in mammals. The product of this gene
is a non-coding RNA that covers the X-chromosome that remains
inactive. Methyl-CpG-binding domain 2 knock out mice do not
present defects during embryonic development but MBD2
deficient females show abnormal maternal behaviour (Hendrich
et al, 2001). However, Apc
(Min/þ) mice (a mouse model for colon
adenomatous polyps) lacking MBD2 show up to 10 times reduced
intestinal tumorigenesis and more localised tumours than those
Apc
(Min/þ) MBD2
þ/þ (Sansom et al, 2003). Moreover, MBD2 level
changes are associated with significant changes at certain
cytokines levels involved in lymphocyte T maturation (Fatemi
and Wade, 2006). A controversial role of MBD2 as a DNA
demethylase has also been proposed (Bhattacharya et al, 1999).
MBD2 has also been related to GSTP1 DNA methylation-
dependent silencing in hepatocellular carcinoma (Bakker et al,
2002). The CpG island of this gene becomes hypermethylated
during the pathogenesis of human hepatocellular carcinoma and
MBD2 appears bound to GSTP1 promoter region leading to gene
silencing.
MBD3
The gene coding MBD3 is located on chromosome 19. Methyl-
CpG-binding domain 3 has two splicing variants that differ in size,
32 and 20kDa. In mammals, MBD3 is unable to bind methylated
DNA due to the presence of two alterations within the MBD.
Despite the lack of a functional methyl-CpG-binding domain,
MBD3 plays an important role in DNA methylation-dependent
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ment (Fatemi and Wade, 2006).
Methyl-CpG-binding domain 3 is an integral subunit of the
chromatin remodelling complex Mi-2/NuRD (Figure 1). This
complex is also composed by histone deacetylases HDAC1 and
HDAC2, histone-binding proteins RbAp46 and RbAp48, the
chromatin-remodelling protein Mi-2 and metastasis-associated
proteins MTA1 and MTA2. Mi-2/NuRD association with
MBD2 leads to MeCP1 complex, initially identified as a methylated
DNA-binding protein and later like a complex containing MBD
proteins.
Mi-2/NuRD-mediated silencing of methylated genes was
hypothesised as starting with MBD2 binding to methylated DNA
followed by Mi-2/NuRD recruitment. However, MBD2 and MBD3
associate to the Mi-2/NuRD complex in a mutually exclusive way
with different biochemistry and functional properties (Le Guezennec
et al, 2006). Proteins interacting with MBD2/Mi-2 complex, but not
with MBD3/Mi-2 complex, have been identified, for instance
PRMT5, an arginine methyltransferase (RMT) (Fabbrizio et al,
2002). This model proposes a mechanism in which methylated
DNA would be recognised by MBD2/Mi-2 complex leading to
arginine methylation and histone hypoacetylation of the histone
next to methylated DNA. This new state of the chromatin structure
would be the target of MBD3 containing Mi-2 complex enhance
histone deacetylation spreading to proximal regions.
MBD4
Methyl-CpG-binding domain 4 is part of the DNA repair
machinery. MBD4 possesses the MBD at the N-terminal region
and a glycosylase domain at the C-terminal region. This protein
recognizes methylated CpG sequences but it has more affinity
for 5mCpG-TpG sequences, a product of 5mCpG dinucleotide
deamination. This deamination of 5-mC to thymine occurs
spontaneously and MBD4 triggers DNA repair at this points by
interacting with MLH1 (mutL homologue 1) (Bellacosa et al, 1999).
MBD4 might also have an essential role in the triggering of
apoptosis upon DNA damage (Zabkiewicz and Clarke, 2004).
MBD4 knock out mice show more cytosine to thymine
transitions at CpG sites (Millar et al, 2002). Moreover, MBD4
 / 
mice with a Apc
(Min/þ) background develop more intestinal
tumours than Apc
(Min/þ) MBD4
þ/þ mice. The correlation
between MBD4 deficiency and intestinal tumorigenesis has also
been assessed in humans, in which 26–43% of microsatellite
unstable colorectal tumours show mutations in the MBD4 gene
(Riccio et al, 1999). Thus, MBD4 might act as a tumour suppressor
gene in human malignancies.
Although MBD4 is mainly related to DNA repair mechanism, it
is also involved in methylation-dependent transcriptional repres-
sion of p16
INK4a and MLH1 genes (Kondo et al, 2005).
OTHER METHYLATED CPG-BINDING PROTEINS
Other proteins with the ability to selectively bind methylated DNA
have been described. The archetypical member of this family of
proteins is Kaiso, a member of the BTB/POZ (POZ/ZF) zinc finger
domain family of proteins that binds methylated CpGs in the
context of a consensus sequence composed by at least two
consecutive methylated CpG dinucleotides. Repressive activity of
Kaiso is mediated by N-CoR corepressor complex, which includes
HDAC3 (Klose and Bird, 2006). Kaiso also recognises the
consensus sequence TCCTGCNA (N being any nucleotide)
throughout a methylated DNA-binding domain independent
region. The affinity for this sequence is higher that the affinity
for methylated CpGs and it could be involved in specific DNA
sequences binding (Daniel et al, 2002). Kaiso knockout mice
intercrossed with Apc
(Min/þ) background are less susceptible to
intestinal tumours (Prokhortchouk et al, 2002) than Apc
(Min/þ)
kaiso
þ/þ mice.
Two other proteins with kaiso like zinc fingers were also
described, ZBTB4 and ZBTB38. Both proteins bind methylated
DNA and it seems that a unique methylated CpG dinucleotide is
sufficient for their binding and gene silencing induction (Filion
et al, 2006).
TARGETING MBD PROTEINS
Methyl-CpG-binding domain proteins are being used in transla-
tional approaches to identify new hypermethylated genes in
human cancer. Three representative examples are the use of
antibodies against MBDs in association with chromatin immuno-
precipitation and genomic arrays (Ballestar et al, 2003), the
association of an MBD to a column that allow the capture of
methylated sequences from stools of patients with colorectal
cancer (Zhou et al, 2007) and the depletion of MBDs to release the
transcriptional silencing of putative tumour suppressor genes
(Lopez-Serra et al, 2008).
Most important, DNA methylation and elements of the
epigenetic machinery constitute very interesting targets for the
design of therapeutic compounds (Esteller 2008). Actually, the use
of demethylating drugs such as 5-azacytidine and 5-aza-20-
deoxycytidine (base analogs that avoid DNMTs function) has
been approved for cancer therapy, specifically for the treatment
of myelodysplastic syndrome and acute myeloid leukaemia. The
unspecific reactivation of methylated sequences is the main
problem of epigenetic treatments. Parallel with demethylation of
tumour suppressor genes CpG islands, global genomic demethyla-
tion, which could cause or contribute to chromosomal instability,
also occurs. Instead of targeting DNA methyltransferases, the
proteins that recognise the signal encoded by DNA methylation
and recruit histone modifying and chromosome remodelling
complexes to these methylated sequences, such as MBDs, could
also be good targets in cancer therapy. This strategy could avoid
problems associated with genomic instability which inhibiting
DNA methylation per se could induce. It is necessary to determine
specific targets of each MBD protein and the exact role they play in
cancer progression to specifically target those involved in each
tumour type. Thus, in a similar manner for the targeted therapy
against gene mutations, there are prospects for the development of
directed epigenetic specific therapy, using for example designed
transcription factors that target particular gene promoters and are
able to re-activate the MBD-silenced gene.
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